Auriga signs manufacturing deal with Mikart
Auriga Laboratories has signed a manufacturing and supply agreement with fellow USA-based Mikart under which the former will have the exclusive rights to market and sell a new product indicated for the relief of mild-to-moderately severe pain in the USA. The new product combines the effects of a centrally-acting analgesic, codeine, with a peripherally-acting painkiller, acetaminophen, in a unique strength previously not available.
According to Auriga, codeine and acetaminophen combinations are one of the most frequently prescribed product classes in the USA, with over 74 million prescriptions written by physicians, generating estimated sales of over $830.0 million each year. The product is expected to launch during the second quarter of 2008, and will be promoted to primary care practitioners and dentists, the firm noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze